// App-Quantinova.ai

4559 : Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.

Researchers

Presenter

  • Begoña Pérez-Valderrama

Principal Investigators

  • Thomas Powles

  • Srikala S. Sridhar

  • Claudia Caserta

  • Yohann Loriot

  • Shilpa Gupta

  • Joaquim Bellmunt

  • Cora N. Sternberg

  • Jing Wang

  • Nuno Costa

  • Robert J Laliberte

  • Alessandra Di Pietro

  • Se Hoon Park

  • Petros Grivas

Medical Centers

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomews Hospital, London, United Kingdom

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Medical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • Cleveland Clinic, Cleveland, OH

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Harvard Medical School, Boston, MA

  • Englander Institute for Precision Medicine, New York, NY.

  • Pfizer Inc., Cambridge, MA

  • Pfizer, Porto Salvo, Portugal

  • Pfizer Inc, Milan, Italy

  • Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea

  • University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

Locations

  • Spain

  • United Kingdom

  • Canada

  • Italy

  • France

  • United States

  • Portugal

  • Republic of South Korea

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Carboplatin

  • Gemcitabine

  • Cisplatin

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02603432

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved